Okklo Life Sciences

Company
Technology
Programs
Partnering
News
Contact
- Where to meet us
- Disclaimer

Via our unique expertise and network we can design novel cyclodextrins for a wide variety of therapeutic areas

Our vision is to be the leading biotech providing cyclodextrin-based therapeutics to improve the life of patients.

Okklo Life Sciences: custom design and development of therapeutic cyclodextrins

Okklo Life Sciences

Novel therapeutic solutions using cyclodextrin-based technologies

Drug Discovery Today

EIT Health Catapult 2022 names health start-up winners 05/26/2022
New £20m Life Sciences Fund Launches to Support SMEs In Greater Manchester, Cheshire and Warrington 05/26/2022
Evonetix Granted Patent for Binary Assembly Method for Gene Synthesis 05/10/2022
Thirona’s RetCAD™ and iCare are joining forces in Europe to offer an integral solution for eye screening with artificial intelligence. 04/29/2022
Proofig launches first commercial automated image duplication and manipulation detection software for scientific publications 04/19/2022

Follow us on:

Recent Okklo News

Okklo’s hematology asset will be further developed by Alveron Pharma 05/16/2019
Okklo and SolAeroMed partner to develop cyclodextrins for cystic fibrosis treatment 06/27/2017
Okklo Life Sciences B.V. and Sanquin sign commercialization agreement to enter IND enabling studies and clinical development. 01/10/2017
Okklo receives RedMedTech Ventures funding and extends collaboration with Sanquin 05/15/2016

Company
Technology
Programs
Partnering
News
Contact

Copyright © 2016 | Okklo Life Sciences | All Rights Reserved